Lisa Hammerle
About Lisa Hammerle
Lisa Hammerle is a scientist at Bristol Myers Squibb with over two decades of experience in biotechnology and pharmaceutical research, specializing in antibody-dependent cellular phagocytosis (ADCP) and cancer treatment.
Current Position at Bristol Myers Squibb
Lisa Hammerle is currently employed as a Scientist at Bristol Myers Squibb. In this role, she has undertaken research projects focused on antibody-dependent cellular phagocytosis (ADCP), specifically investigating its effects on acute myeloid leukemia (AML) and B-cell lymphoma. Her work in this field contributes to the advancement of therapeutic strategies and drug development.
Previous Roles and Experience
Lisa Hammerle's experience includes various significant roles in the biotechnology and pharmaceutical sectors. Prior to her current position, she served as a Senior Associate Scientist at Bristol Myers Squibb, a role she held for 3 months in Seattle, Washington from 2020 to 2021. She also worked at Novo Nordisk as a Senior Associate Scientist from 2016 to 2020 and held several positions at Amgen, including Sr. Associate Scientist and Associate Scientist, from 2001 to 2015. Additionally, Hammerle held the position of Temporary Research Associate IV at PhaseRx and Research Technologist at the University of Washington's Department of Medicine.
Educational Background
Lisa Hammerle obtained a Bachelor of Science (BS) in Cell/Cellular and Molecular Biology from the University of Washington. She also earned a Bachelor of Science (BS) in Environmental Science from Western Washington University. This diverse educational background provides her with a robust foundation in both environmental and cellular sciences, facilitating her comprehensive approach to research in the pharmaceutical and biotechnology industries.
Specialization in Antibody-Dependent Cellular Phagocytosis (ADCP)
Lisa Hammerle specializes in antibody-dependent cellular phagocytosis (ADCP), especially in the context of acute myeloid leukemia and B-cell lymphoma. Her research at Bristol Myers Squibb involves studying ADCP to understand its potential in therapeutic applications. This specialization is a critical aspect of her contributions to advancing cancer treatments and improving patient outcomes.
Extensive Experience in Translational Research
With over two decades dedicated to translational research, Lisa Hammerle has explored various drug combinations for cancer treatment. Her extensive experience in this area involves bridging the gap between laboratory research and clinical application, ensuring that scientific discoveries translate effectively into therapeutic strategies. Her work has significantly contributed to the understanding and development of cancer treatments.